Cochlear: FDA approves new Nucleus Profile Plus implant series with Android smartphone connectivity
CENTENNIAL -- Cochlear Limited ( ASX: COH), a global leader in implantable hearing solutions, today announced the U.S. Food and Drug Administration's approval of the new Cochlear Nucleus ... Read More
Monday June 17, 2019 0 comments
Clovis Oncology receives Breakthrough Therapy designation for Rubraca
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced theU.S. Food and Drug Administration(FDA) has granted Breakthrough Therapy designation for Rubraca (rucaparib) as a monotherapy... Read More
Tuesday October 2, 2018 0 comments
Array BioPharma colorectal cancer drugs receive Breakthrough Therapy Designation from FDA
BOULDER -- Array BioPharma Inc. (NASDAQ: ARRY) today announced it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for encorafenib (BRAFTOVI),... Read More
Tuesday August 7, 2018 0 comments
Array BioPharma: National Comprehensive Cancer Network, FDA OKs drug combo for melanoma
BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) announced that the National Comprehensive Cancer Network (NCCN) has updated the Clinical Practice Guidelines in Oncology for Melanoma to include... Read More
Monday July 16, 2018 0 comments
Fischer Medical receives FDA clearance to market Bloom2 cardiac stimulator
WHEAT RIDGE -- Fischer Medical announced its Bloom2 cardiac electrophysiology stimulator device has received U.S. Food and Drug Administration 510(k) clearance. The Bloom2 stimulator is a... Read More
Tuesday April 10, 2018 0 comments
Clovis Oncology submits NDA for rucaparib to treat recurrent ovarian cancer
BOULDER -- Clovis Oncology (NASDAQ: CLVS) today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for rucaparib as maintenance... Read More
Tuesday October 10, 2017 0 comments
InDevR licenses FDA influenza antibodies for VaxArray potency platform
BOULDER -- InDevR , a Boulder-based progressive analytical technology and life science instrumentation company, today announced it has entered into an agreement to license monoclonal antibodies... Read More
Tuesday January 17, 2017 0 comments
Ampio: FDA discussions continue on best path forward for Ampion
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it is continuing discussions with the CBER Division of the FDA to determine the best path forward to obtain a Biological... Read More
Thursday November 10, 2016 0 comments
IN Sponsors
Browse
Entrepreneurial by Nature
